InvestSMART

Acrux Limited (ASX:ACR)

ALERT: Price-sensitive ASX Announcement for ACR
Current share price for ACR : $0.009 -0.001 (-10%)+
Announcement
Release
31 Jul 2026 10:07AM
Price at Release
$0.010
Full Release
download
Summary
The document is Acrux Limited's Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter ending 30 June 2026. It outlines significant financial milestones, including a 960% increase in receipts from customers to $5.002 million for FY26, with $1.780 million received in the June quarter alone. Acrux achieved its first licensing milestone of $1.350 million from Gedeon Richter Plc for Lenzetto® in Australia. The company also raised $1.6 million through a share placement to fund the development of Female Testosterone. Financial operations include a net cash inflow from operating activities and strategic investments in Female Testosterone, an asset being developed for Hypoactive Sexual Distress Disorder (HSDD), with Phase III clinical trials planned. The report emphasizes Acrux's focus on commercial development and partnerships, especially in women's health, and outlines its financing activities, including facilities with Radium Capital and ANZ Bank. Acrux maintains a stable cash position with estimated funding for 9 quarters.
Key Points
  • Acrux's FY26 customer receipts grew 960% year-on-year.
  • First licensing milestone of $1.350 million from Gedeon Richter Plc.
  • Received $1.6 million from institutional investors via share placement.
  • Focus on developing Female Testosterone for HSDD.
  • Phase III clinical trials for Female Testosterone planned.
  • Net cash from operating activities reported.
  • No new short-term advances from Radium Capital in June 2026.
  • Acrux's cash and cash equivalents at quarter end: $1.705 million.
  • Total available funding is estimated to last for 9 quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.